Teva Pharmaceutical Industries Ltd. Meets Earnings Targets Despite a Mild European Winter

Teva's sales suffered from a mild winter in Europe and Russia, but strong sales of specialty drugs evened the first-quarter score.

May 1, 2014 at 12:00AM
Teva Logo

Image source: Teva.

Pharmaceutical specialist Teva (NYSE:TEVA) just announced results for the first quarter of 2014.

Sales increased 2% year over year to $5 billion, falling short of the $5.1 billion analyst consensus. Teva's earnings increased 8% to $1.22 per share and American Depositary Receipt, matching Wall Street's expectations.

The generics segment reported 3% year-over-year sales growth, accounting for 46% of Teva's total revenue. The segment was helped by the release of new medications in Europe and North America, but hindered by a mild European winter and increased competition in America.

In the specialty segment, sales increased by 3%. The gain was driven by more than 20% growth in Parkinson's disease treatment Azilect, narcolepsy medication Nuvigil, and asthma inhalator drug ProAir.

The over-the-counter division saw sales of $269 million, a 12% decrease from the year-ago period. This drop was driven by "an exceptionally weak cough and cold season in Europe and Russia," according to Teva.

The Israel-based company launched a modified version of its blockbuster Copaxone multiple sclerosis medication during the quarter. About one-third of all Copaxone patients in America have already switched to the new thrice-a-week dosing schedule.

"We are intensely focused on solidifying the foundation of Teva, maintaining the Copaxone franchise, driving sustainable organic growth, and positioning Teva for long-term value creation," said CEO Erez Vigodman in a prepared statement.

Anders Bylund has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information

Compare Brokers